Length of activity: 60 minutes Approved for 1 AMA PRA Category 1 Credits™ Dr. Maria Chiara Garassino and Dr. Maurice Pérol, discuss recent developments in clinical research and how these can be translated into clinical practice. Prof. Enriqueta Felip and Prof. Sanjay Popat provide insight on the future management of patients with advanced NSCLC using clinical case studies.
THIS CONTENT IS AVAILABLE FOR FREE TO REGISTERED USERS You are not currently logged in. LOGIN or REGISTER to access this content
LOGIN or REGISTER to access this content
Immediate, and unrestricted free access to all resources
Earn AMA PRA Category 1 Credits™ for completing accredited activities
Bi-weekly scientific newsletters highlighting the latest emerging data and industry news
Access to your personalised learning profile and CME record.
Watch an internationally renowned faculty discuss the changing treatment paradigms in advanced NSCLC, including the current and future role of immunotherapy.
Dr. Maria Chiara Garassino and Dr. Maurice Pérol, discuss recent developments in clinical research and how these can be translated into clinical practice. Professor Enriqueta Felip and Professor Sanjay Popat (Chair) then provide insight on the future management of patients with advanced NSCLC using clinical case studies.
The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with lung cancer.
This ACCME-accredited touchSATELLITE SYMPOSIUM was recorded live during the ESMO Immuno-Oncology Congress in December 2018. The live voting content is no longer active for this symposium.
After watching this touchSATELLITE SYMPOSIUM, you should:
Recognize the current unmet needs in patients with advanced NSCLC without an oncogenic driver and be aware of the continuing role for chemotherapy.
Understand the patient and disease factors that determine optimal use and sequencing of chemotherapy, immunotherapy and immuno-chemotherapy in order to maximize individual outcomes in this patient group.
Be familiar with unresolved questions regarding the use of immunotherapy in patients with advanced NSCLC, including the use of PD-L1 as a biomarker.
1 AMA PRA Category 1 Credits™ Date of original release: March 7, 2019 Date credits expire: March 7, 2020
Harnessing the power of immunotherapy in advanced non-small cell lung cancer: how do we navigate the increasingly complex patient pathway without an oncogenic driver?
1 AMA PRA Category 1 Credits™ Date of original release: March 7, 2019 Date credits expire: March 7, 2020
Primary lung cancer is the leading cause of cancer mortality, of which around 85% is classified as non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors are revolutionizing the treatment of advanced NSCLC without an oncogenic driver. However, translating the overwhelming amount of new data into clinical practice is a challenge. The expert faculty address key questions such as which agents may benefit which patients? In what sequence should they be used? What is the role of biomarkers in treatment decisions? Interactive case studies then consider current and future management of advanced NSCLC to continue optimizing patient outcomes.
Module 1: Driving forwards with immunotherapy in NSCLC – latest advances
Dr. Marina Chiara Garassino, MDdescribes the latest clinical data for advanced NSCLC and how these results impact on clinical practice. She provides an overview of the available checkpoint inhibitors and their mechanisms of action, including data from key clinical trials investigating first-line options for patients with NSCLC without oncogenic driver mutations.
Module 2: Driving forwards with immunotherapy in NSCLC – applications for clinical practice
Dr. Maurice Pérol, MD discusses how the latest clinical data for advanced NSCLC can be translated in the clinic. He reviews patient selection, and examines the clinical relevance of PD-L1 and tumour mutational burden as biomarkers. He also highlights clinical challenges around management of the increased toxicity observed with immunotherapy-chemotherapy combination treatment.
Module 3: Navigating the complex patient pathway in NSCLC without an oncogenic driver
Professor Enriqueta Felip, MD and Professor Sanjay Popat, FRCP PhD present two interactive cases covering the practical aspects of patient management, including diagnosis, treatment selection, adverse event management and refractory/aggressive disease.
Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Reader in Cancer Medicine at Imperial College, London, UK.
Sanjay Popat is an internationally recognized expert in the treatment of lung cancer, mesothelioma and thymoma. He chairs the British Thoracic Oncology Group (BTOG), and is immediate past Chair of the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He has been elected onto the Foundation Council of the European Thoracic Oncology Platform (ETOP), and is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group and the International Thymic Malignancy Interest Group (ITMIG).
Disclosures: Honoraria and consulting from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, EMD Serono, Guardant Health, Medscape, MSD, Novartis, OncLive, Pfizer, Roche, Takeda, Tesaro, TouchIME. Research grant from Boehringer Ingelheim.
Chief of the Thoracic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Marina Chiara Garassino leads the strategy for clinical and translational research in advanced and locally advanced NSCLC, mesothelioma and thymic malignancies in the Thoracic Oncology Unit. Her main research interests are NSCLC, SCLC, mesothelioma and development of biomarkers. She served as ESMO National Representative for 5 years (2011-2017) and is a member of several ESMO Task forces (Public Policy extended Committee, Press Committee, Publishing Working Group, Women for Oncology). She is the founder and president of Women for Oncology Italy.
Disclosures: Honoraria and consulting from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Genentech, MSD, Novartis, Pfizer, Roche, Takeda. Research grant from Merck.
Associate Professor of Pneumology, Léon Bérard Cancer Center, Lyon, France
Maurice Pérol is a past Chairman of the Groupe Français de Pneumo-Cancérologie (GFPC) and executive Board member of the French Cooperative Group of Thoracic Oncology “Intergroupe Francophone de Cancérologie Thoracique” (IFCT). His research experience includes clinical phase I, II and III studies in lung cancer, especially in advanced non-small cell lung cancer. He was the principal investigator of the two IFCT-GFPC maintenance French studies which involved more than 70 centers in France and the co-primary investigator of the international phase III REVEL study for the development of ramucirumab in advanced non-small cell lung cancer.
Disclosures: Honoraria and consulting from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Clovis Oncology, Eli Lilly, Genentech, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Takeda. Research grant from AstraZeneca, Chugai, Roche.
Head of the Thoracic Tumors Group, Vall d’Hebron University Hospital, Barcelona, Spain
Enriqueta Felip is responsible for thoracic cancer trials undertaken at the Vall d’Hebron University Hospital. She is also Associate Professor at the Autonomous University of Barcelona (UAB). She was Subject Editor of Guidelines Working group ESMO Minimum Clinical Recommendations in lung cancer and Coordinator of the 1st ESMO Consensus Conference in lung cancer. She is currently a member of the scientific committee of the Spanish Lung Cancer Group and coordinator of the European School of Oncology (ESO) lung cancer program.
Disclosures: Honoraria and consulting from AbbVie, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Guardant Health, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda. Research grant from Fundación Merck Salud, Grant for ONcology Innovation EMD Seron.
1. Shih K, Arkenau H-T, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014;74:1993-2013.
2. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31(23):2895-902.
3. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078-92.
4. Brahmer JR. Health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%: data from KEYNOTE-024. WCLC 2017; abstr PL04a.01.
5. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. NEJM 2016;375:1823-33.
6. Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol 2018;36(Suppl; abstr LBA4).
7. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017;376(25):2415-26.
8. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT02453282, Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC). Available from: https://clinicaltrials.gov (Accessed: 13 March 2019).
9. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017;376(25):2415-26 Supplementary Appendix.
10. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. NEJM 2018;378:2288-2301.
11. Naidoo J, Drilon A.Molecular diagnostic testing in non-small cell lung cancer. AJHO 2014;10(4):4-11.
12. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017;18(7):895-903.
13. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl 4);iv119-iv142.